Answers are grounded in this paper and cite their sources.
Interstitial lung diseases (ILD) have a high mortality and morbidity rate. Outcomes after TAVR in patients with ILD are unknown. We sought to assess the outcome of TAVR in patients with ILD. This is an analysis of the National Inpatient Sample of the years 2016 to 2020. We identified patients who were admitted with for TAVR procedure using ICD10 PCS codes. The risk of mortality and in-hospital complications in the interstitial lung disease group was compared to the non–interstitial lung disease group using multivariate logistic regression analysis. During 2016-2020, there were a total of 297,545 patients who were admitted for TAVR in the US of which 545 patients (0.2%) had ILD, 297000(98.8%) had absence of ILD. Mean LOS was 3.57 days in ILD group vs 3.87days in non ILD group, while the mean total cost of care was 202727$ in the ILD group vs 217008 $ in the non-ILD group. After adjusting for demographics, smoking status, COPD, dependence on long term oxygen, history of lung transplant and OSA, Higher odds of respiratory failure were seen in the ILD group compared to non–ILD group (aOR (adjusted odds ratio) 2.22; 95% CI 1.24–3.95 p=0.007). There were similar odds of in-hospital mortality, MI, GI bleed and pneumothorax in both groups. (Table 1) TAVR in ILD patients has higher odds of respiratory failure compared to non-ILD group. Observational studies and RCTs are needed to elucidate it further.
No takes yet. Share an insight, caveat, or question.
Mir et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: